The Japanese government is actively working to restore drug discovery capabilities, aiming to create a revitalized ecosystem that can contribute to domestic and global drug development.
However, these efforts continue to be undermined by remaining constraints on Japan’s rewards for innovation in its drug pricing system – even for novel drugs in key areas like rare diseases and pediatrics, where Japan clearly wants more research and development and faster deployment of innovative remedies.
The Asia Group (TAG) assesses that strict cost disclosure requirements, especially the “zero co-factor” rule under the cost-based price calculation method, directly undermine the government’s goal of bringing innovative new pharmaceutical products to the Japanese market, including the targets laid out in the Japanese government’s five-year plan for the development and approval of pediatric and rare disease drugs.
The Japanese government should consider either adjustments to these rules or introducing an entirely new way of pricing and rewarding innovative medicines to adequately reflect these products’ value at launch. Such changes will facilitate innovative medicines’ faster entry into Japan, ultimately benefiting patients and contributing to the revitalization of Japan’s drug innovation ecosystem.
Media
Commentary
Japan’s Drug Innovation Incentive Policies: Policy Challenges Undermine Desired Goals (ENG)
Key Takeaways
Listen on:
Related Posts
Han Lin in Bloomberg: Futuristic Shenzhen Show Trump the Difficulty of Stopping China
George Chen in The Straits Times on whether Trump will take a tougher stance on China after his election setback
Han Lin in The Straits Times: Post Midterm Elections, Asia Faces a More Constrained But No Less Unpredictable Trump
Ashok Malik in The Economic Times: “Reset will keep India busy as Trump’s midterm loss redraws US politics”